X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (411) 411
Publication (24) 24
Book Review (10) 10
Newsletter (4) 4
Book Chapter (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (323) 323
index medicus (281) 281
respiratory system (204) 204
asthma (198) 198
administration, inhalation (188) 188
pulmonary disease, chronic obstructive - drug therapy (166) 166
fluticasone (165) 165
male (160) 160
female (159) 159
salmeterol (157) 157
treatment outcome (144) 144
asthma - drug therapy (141) 141
fluticasone propionate (131) 131
middle aged (131) 131
chronic obstructive pulmonary disease (126) 126
obstructive pulmonary-disease (122) 122
adult (120) 120
lung diseases, obstructive (120) 120
bronchodilator agents - administration & dosage (119) 119
corticosteroids (118) 118
drug therapy (118) 118
drug combinations (116) 116
drug therapy, combination (111) 111
aged (105) 105
inhaled corticosteroids (100) 100
copd (99) 99
double-blind (96) 96
albuterol - analogs & derivatives (88) 88
bronchodilator agents - therapeutic use (88) 88
pulmonary disease, chronic obstructive - physiopathology (81) 81
androstadienes - administration & dosage (74) 74
double-blind method (74) 74
pharmacology & pharmacy (74) 74
adrenal cortex hormones - administration & dosage (73) 73
budesonide (72) 72
formoterol (70) 70
quality of life (66) 66
exacerbations (65) 65
tiotropium (64) 64
androstadienes - therapeutic use (63) 63
bronchodilator agents - adverse effects (62) 62
dosage and administration (62) 62
research (62) 62
pulmonary disease, chronic obstructive - diagnosis (61) 61
efficacy (60) 60
salmeterol xinafoate (59) 59
diseases of the respiratory system (58) 58
fluticasone propionate/salmeterol (58) 58
care and treatment (56) 56
lung-function (55) 55
adrenergic beta-2 receptor agonists - administration & dosage (54) 54
albuterol - administration & dosage (54) 54
albuterol - therapeutic use (53) 53
anti-asthmatic agents - therapeutic use (53) 53
medicine, general & internal (52) 52
safety (52) 52
adolescent (49) 49
original research (49) 49
severity of illness index (49) 49
therapy (48) 48
adrenal cortex hormones - therapeutic use (47) 47
anti-asthmatic agents - administration & dosage (46) 46
forced expiratory volume (46) 46
lung - physiopathology (46) 46
mortality (46) 46
fluticasone-salmeterol drug combination (45) 45
respiratory tract diseases (45) 45
asthma - physiopathology (44) 44
pulmonary and respiratory medicine (44) 44
salmeterol/fluticasone propionate (44) 44
studies (44) 44
allergy (43) 43
analysis (43) 43
formoterol fumarate (43) 43
metered-dose inhaler (43) 43
lung - drug effects (42) 42
disease progression (40) 40
international journal of chronic obstructive pulmonary disease (40) 40
persistent asthma (40) 40
propionate (40) 40
review (40) 40
cardiac & cardiovascular systems (39) 39
glucocorticoids - administration & dosage (39) 39
medicine & public health (39) 39
pulmonary/respiratory (39) 39
risk factors (39) 39
internal medicine (38) 38
pneumonia (38) 38
quality-of-life (38) 38
respiratory agents (38) 38
time factors (37) 37
adrenergic beta-2 receptor agonists - adverse effects (36) 36
androstadienes - adverse effects (36) 36
clinical trials (36) 36
combination therapy (36) 36
drug administration schedule (36) 36
patients (36) 36
randomized controlled trials as topic (35) 35
steroids (35) 35
aged, 80 and over (34) 34
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 8, pp. 1171 - 1179
Summary Background Fluticasone furoate/vilanterol (FF/VI) is an inhaled corticosteroid/long-acting beta2 -agonist (ICS/LABA), recently approved as once-daily... 
Pulmonary/Respiratory | Head-to-head | Long-acting β2-agonist | Chronic obstructive pulmonary disease | Lung function | Inhaled corticosteroid | VILANTEROL | CARDIAC & CARDIOVASCULAR SYSTEMS | MU-G | LUNG-FUNCTION | RANDOMIZED-TRIAL | PERSISTENT ASTHMA | Long-acting beta-agonist | FUROATE | SALMETEROL | RESPIRATORY SYSTEM | EXACERBATIONS | AGONIST | Glucocorticoids - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Benzyl Alcohols - administration & dosage | Benzyl Alcohols - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Chlorobenzenes - administration & dosage | Vital Capacity - drug effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Albuterol - administration & dosage | Female | Glucocorticoids - adverse effects | Dry Powder Inhalers | Double-Blind Method | Drug Administration Schedule | Administration, Inhalation | Albuterol - analogs & derivatives | Treatment Outcome | Androstadienes - administration & dosage | Chlorobenzenes - adverse effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Fluticasone-Salmeterol Drug Combination | Androstadienes - adverse effects | Albuterol - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Corticosteroids | Studies | Confidence intervals | Drug therapy
Journal Article
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2011, Volume 106, Issue 3, pp. 382 - 389
Summary Background The combination of tiotropium and fluticasone propionate/salmeterol (FSC) is commonly used to treat chronic obstructive pulmonary disease... 
Pulmonary/Respiratory | Tiotropium | Fluticasone propionate/salmeterol | Chronic obstructive pulmonary disease | Lung function | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | SAFETY | PREVENTION | COMBINATION | SALMETEROL | PROPIONATE | TRIAL | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | EXACERBATIONS | Bronchodilator Agents - therapeutic use | Glucocorticoids - therapeutic use | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Scopolamine Derivatives - administration & dosage | Female | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Scopolamine Derivatives - therapeutic use | Glucocorticoids - adverse effects | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Acute Disease | Albuterol - analogs & derivatives | Treatment Outcome | Algorithms | Quality of Life | Albuterol - therapeutic use | Aged | Androstadienes - therapeutic use | Fluticasone-Salmeterol Drug Combination | Androstadienes - adverse effects | Albuterol - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Medical colleges | Allergy | Lung diseases, Obstructive | Fluticasone | Comparative analysis | Allergic reaction | Steroids | Hospitalization | Disease | Drug therapy | Bias | Quality of life
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2011, Volume 106, Issue 1, pp. 91 - 101
Journal Article
Chest, ISSN 0012-3692, 09/2006, Volume 130, Issue 3, pp. 647 - 656
To examine the effect of fluticasone propionate, 250 μg/salmeterol, 50 μg combination (FSC 250/50) twice daily on lung hyperinflation and associated measures... 
long-acting β2-agonist | lung hyperinflation | salmeterol | fluticasone propionate | exercise | inhaled corticosteroid | COPD | Exercise | Inhaled corticosteroid | Salmeterol | agonist | Long-acting β | Lung hyperinflation | Fluticasone propionate | INSPIRATORY CAPACITY | DYSPNEA | PERFORMANCE | long-acting beta-agoinst | FLOW LIMITATION | INHALED BRONCHODILATORS | SALMETEROL | PROPIONATE | OBSTRUCTIVE PULMONARY-DISEASE | DYNAMIC HYPERINFLATION | RESPIRATORY SYSTEM | TIOTROPIUM | CRITICAL CARE MEDICINE | Bronchodilator Agents - therapeutic use | Albuterol - pharmacology | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Pulmonary Disease, Chronic Obstructive - pathology | Physical Endurance - physiology | Lung Volume Measurements | Dose-Response Relationship, Drug | Respiratory Mechanics - drug effects | Time Factors | Pulmonary Ventilation - physiology | Female | Adrenergic beta-Agonists - therapeutic use | Bronchodilator Agents - adverse effects | Respiratory Mechanics - physiology | Adrenergic beta-Agonists - adverse effects | Tidal Volume - physiology | Lung - pathology | Salmeterol Xinafoate | Double-Blind Method | Pulmonary Ventilation - drug effects | Adrenergic beta-Agonists - pharmacology | Albuterol - analogs & derivatives | Bronchodilator Agents - pharmacology | Dyspnea - physiopathology | Lung - physiopathology | Androstadienes - pharmacology | Lung - drug effects | Albuterol - therapeutic use | Aged | Androstadienes - therapeutic use | Fluticasone-Salmeterol Drug Combination | Respiratory Function Tests | Androstadienes - adverse effects | Physical Endurance - drug effects | Tidal Volume - drug effects | Albuterol - adverse effects | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Usage | Corticosteroids | Propionates | Research | Drug therapy
Journal Article
Journal Article
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2011, Volume 105, Issue 9, pp. 1322 - 1330
Summary Background COPD is associated with increased arterial stiffness which may in part explain the cardiovascular morbidity observed in the disease. A... 
Pulmonary/Respiratory | Aortic pulse wave velocity | Augmentation index | Emphysema | Computed tomography scanning | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | PULSE-WAVE VELOCITY | CARDIOVASCULAR EVENTS | LUNG-FUNCTION | RISK | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | INFLAMMATION | CORTICOSTEROIDS | Forced Expiratory Volume - drug effects | Albuterol - pharmacology | Humans | Middle Aged | Sympathomimetics - pharmacology | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Vascular Resistance - drug effects | Female | Sympathomimetics - adverse effects | Cardiovascular Diseases - physiopathology | Double-Blind Method | Albuterol - analogs & derivatives | Treatment Outcome | Arteries - drug effects | Pulmonary Disease, Chronic Obstructive - complications | Androstadienes - pharmacology | Arteries - physiopathology | Cardiovascular Diseases - chemically induced | Fluticasone-Salmeterol Drug Combination | Androstadienes - adverse effects | Albuterol - adverse effects | Drug Combinations | Blood Flow Velocity - drug effects | Pulmonary Disease, Chronic Obstructive - drug therapy | Hypertension | Medical colleges | Lung diseases, Obstructive | Care and treatment | Fluticasone | Steroids | Studies | Heart attacks | Medical imaging | Royalties | Nitric oxide | Educational materials | Diabetes | Drug therapy | Pharmaceutical industry
Journal Article
Journal of Asthma, ISSN 0277-0903, 09/2018, Volume 55, Issue 9, pp. 984 - 993
Objective: We aimed to demonstrate non-inferiority of once-daily fluticasone furoate/vilanterol 100/25 µg (FF/VI) to twice-daily fluticasone... 
switching | Fluticasone furoate | vilanterol | LABA | ICS | once daily | agonist | maintained | long-acting β | inhaled corticosteroid | stepping across
Journal Article
Journal Article
BMC Pulmonary Medicine, ISSN 1471-2466, 04/2017, Volume 17, Issue 1, pp. 75 - 12
Background: To analyse the efficacy of fluticasone propionate (FP) alone and combined with salmeterol (SAL) in achieving guideline-defined asthma control in... 
Fluticasone propionate/salmeterol | Asthma control | Asthma treatment | Asian patients | ICS/LABA treatment | Asthma | MANAGEMENT | RELIEVER THERAPY |